Lv1
80 积分 2024-08-19 加入
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
2天前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
3天前
已完结
9MW2821, a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open label, multicenter, phase Ⅰ/Ⅱ study
3天前
已关闭
MONO-OLA1: A randomized, phase III study of olaparib maintenance monotherapy in patients with BRCA wild-type advanced ovarian cancer following response to first-line platinum-based chemotherapy (334)
4天前
已关闭
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
5天前
已完结
High sensitivity circulating tumor-DNA assays in Renal Cell Carcinoma – Are we there yet?
7天前
已关闭
Diagnostic liquid biopsy biomarkers in renal cell cancer
7天前
已完结
Current Status of Predictive Biomarker Development in Metastatic Renal Cell Carcinoma
7天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
11天前
已完结
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
11天前
已完结
皖公网安备34019202002308
